Regulatory nod for conducting clinical trials of Colchicine on COVID-19 patients: CSIR


PTI, Jun 12, 2021, 1:34 PM IST

The Drugs Controller General of India (DCGI) has given approval to the CSIR and Laxai Life Sciences Private Limited to conduct clinical trial of Colchicine on COVID-19 patients, according to a statement on Saturday.

Ram Vishwakarma, the advisor to the CSIR Director General, said Colchicine in combination with standard care will be an important therapeutic intervention for COVID-19 patients with cardiac co-morbidities and also for reducing pro-inflammatory cytokines, leading to faster recovery. A number of global studies have confirmed that cardiac complications during course of COVID-19 infections and post-Covid syndrome are leading to loss of many lives, and it is essential to look for new or repurposed drugs, he said.

”Council of Scientific & Industrial Research (CSIR), and Laxai Life Sciences Pvt Ltd Hyderabad, have been given the regulatory approval by DCGI to undertake a two-arm phase-II clinical trial to assess the safety and efficacy of the drug Colchicine in improvement of clinical outcomes during the treatment of COVID-19 patients,” the statement said. The partner CSIR institutes in this important clinical trial are the CSIR-Indian Institute of Chemical Technology (IICT), Hyderabad and CSIR-Indian Institute of Integrative Medicine (IIIM), Jammu.

India is one of the largest producers of this key drug and if successful, it will be made available to patients at an affordable cost, IICT Director S Chandrasekhar said.

Laxai Life Sciences CEO Ram Upadhayay said the enrolment of patients has already begun at multiple sites across India and the trial is likely to be completed in the next 8-10 weeks. He further added that this drug can be made available to a large population of India based on the results of this trial and regulatory approval.

Last week, the CSIR announced that it along with Laxai Life Sciences Pvt Ltd has initiated phase II clinical trials of anti-helminitic drug Niclosamide for treatment of COVID-19.

Niclosamide has been extensively used in the past for treatment of tapeworm infection in adults as well as children. The safety profile of this drug has been tested over time and has been found safe for human consumption at different dose levels, the CSIR said.

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

Siddaramaiah slams Central govt’s decision to import areca nut from Bhutan

BRS has no plans to contest K’taka Assembly polls: Kumaraswamy

Karnataka govt to open ‘Namma Clinics’ in the state

Hindi trailer of Rishab Shetty-starrer ‘Kantara’ ready for release on Oct 9

India’s heaviest rocket to make global foray on October 22

SA score 249 for 4 against India in rain-curtailed first ODI

BJP to hold mega events, tour programmes of key party leaders ahead of elections in Karnataka


Related Articles More

Run campaign to make UP roads pothole-free by Nov 15: Yogi to officials

Punjab CM Mann seeks support of farmers for paddy stubble management to protect environment

Foreign vessel with drugs seized off Kochi coast

Newly launched Mumbai-Gandhinagar Vande Bharat train suffers minor damage after hitting buffaloes

‘Even my wife doesn’t scold me as much as LG sahib’: Kejriwal asks Saxena to ‘chill a bit’

MUST WATCH

Running Reace with Rahul Gandi and Siddaramiah

Uchila Dasara 2022 : Final Preparation for Precession

Bharath Judo : Rahul Gandhi Speach in Rain

Day 8 | Mahagauri

Sarapady Devadas Special Video.


Latest Additions

Run campaign to make UP roads pothole-free by Nov 15: Yogi to officials

Siddaramaiah slams Central govt’s decision to import areca nut from Bhutan

Punjab CM Mann seeks support of farmers for paddy stubble management to protect environment

Implement Justice Nagamohan Das Commission report to increase reservation for SCs, STs in Karnataka: Rahul Gandhi

UNHRC adopts resolution against Sri Lanka’s rights record; India abstains from voting

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.